

Andrea Gombos

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7977661/publications.pdf>

Version: 2024-02-01

18
papers

841
citations

759190

12
h-index

794568

19
g-index

19
all docs

19
docs citations

19
times ranked

1651
citing authors

#	ARTICLE	IF	CITATIONS
1	Abemaciclib, a third CDK 4/6 inhibitor for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 81-92.	2.4	6
2	FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 125.	5.2	9
3	Who are the women who enrolled in the POSITIVE trial: A global study to support young hormone receptor positive breast cancer survivors desiring pregnancy. <i>Breast</i> , 2021, 59, 327-338.	2.2	31
4	MOMENTUM: A Phase I Trial Investigating 2 Schedules of Capecitabine With Aflibercept in Patients With Gastrointestinal and Breast Cancer. <i>Clinical Colorectal Cancer</i> , 2020, 19, 311-318.e1.	2.3	4
5	Investigational drugs in early stage clinical trials for the treatment of HER2+ breast cancer. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 617-627.	4.1	6
6	Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1bâ€“2 trial. <i>Lancet Oncology</i> , The, 2019, 20, 371-382.	10.7	327
7	Selective oestrogen receptor degraders in breast cancer. <i>Current Opinion in Oncology</i> , 2019, 31, 424-429.	2.4	24
8	Recent advances in understanding breast cancer and emerging therapies with a focus on luminal and triple-negative breast cancer. <i>F1000Research</i> , 2019, 8, 591.	1.6	15
9	Advances in chemical pharmacotherapy to manage advanced breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 95-103.	1.8	4
10	Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE). <i>European Journal of Cancer</i> , 2017, 85, 133-145.	2.8	84
11	Targeting immune checkpoints in breast cancer: an update of early results. <i>ESMO Open</i> , 2017, 2, e000255.	4.5	118
12	Results of the Belgian expanded access program of eribulin in the treatment of metastatic breast cancer closely mirror those of the pivotal phase III trial. <i>European Journal of Cancer</i> , 2016, 60, 117-124.	2.8	22
13	Pharmacodynamics, pharmacokinetics and clinical efficacy of neratinib in HER2-positive breast cancer and breast cancer with HER2 mutations. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016, 12, 947-957.	3.3	23
14	Emerging drugs targeting human epidermal growth factor receptor 2 (HER2) in the treatment of breast cancer. <i>Expert Opinion on Emerging Drugs</i> , 2016, 21, 91-101.	2.4	26
15	Cytotoxic chemotherapy: Still the mainstay of clinical practice for all subtypes metastatic breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 100, 74-87.	4.4	69
16	Feasibility Study of EndoTAG-1, a Tumor Endothelial Targeting Agent, in Combination with Paclitaxel followed by FEC as Induction Therapy in HER2-Negative Breast Cancer. <i>PLoS ONE</i> , 2016, 11, e0154009.	2.5	27
17	Evaluating the pharmacokinetics and pharmacodynamics of everolimus for treating breast cancer. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 823-834.	3.3	3
18	Clinical development of insulin-like growth factor receptorâ€“1 (IGF-1R) inhibitors: At the crossroad?. <i>Investigational New Drugs</i> , 2012, 30, 2433-2442.	2.6	42